Derma Sciences (NASDAQ:DSCI) which is known for some of the medical device equipment it makes has received a lowered rating of neutral or hold from a number of investment analysis companies from buy.
The latest lowering of the rating comes from Roth Capital whose analysts have lowered the company’s rating from a “buy” rating to a “neutral” rating in a report issued on Wednesday. The company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.
Zacks Investment Research had also downgraded Derma Sciences from a “buy” rating to a “hold” rating late last year. On Wednesday, stocks of Derma Sciences (NASDAQ:DSCI) traded down 0.357 per cent during midday trading reaching $6.975. During the trading period, as many as 50,026 shares of the company were exchanged.
Derma Sciences (NASDAQ:DSCI) last released its quarterly earnings results on Thursday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.01. The firm had revenue of $21.80 million for the quarter, compared to the consensus estimate of $23.90 million. Derma Sciences had a negative net margin of 12.32 per cent and a negative return on equity of 4.09 per cent. On average, analysts forecast that Derma Sciences will post ($0.12) earnings per share for the current fiscal year.
Some of the position changes in the stock of Derma Sciences by hedge funds and other institutional investors are as below:
- Emerald Acquisition Ltd. bought a new position in shares of Derma Sciences during the second quarter worth about $202,000.
- Dimensional Fund Advisors LP increased its position in shares of Derma Sciences by 15.6 per cent in the second quarter.
- Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Derma Sciences by 35.5 per cent in the third quarter.
- Jacobs Levy Equity Management Inc. increased its position in shares of Derma Sciences by 170.5 per cent in the first quarter.
- BlackRock Institutional Trust Company N.A. increased its position in shares of Derma Sciences by 2.4 per cent in the second quarter.
Institutional investors own 59.12 per cent of the company’s stock.